Access and Publication Clause Samples
The Access and Publication clause governs the rights and procedures related to accessing information or materials and the conditions under which such information may be published. Typically, this clause outlines who is permitted to access certain data, documents, or results, and sets forth the process for seeking approval before any public disclosure or publication occurs. For example, it may require parties to notify each other before publishing research findings or to obtain written consent prior to sharing proprietary information. The core function of this clause is to protect sensitive or confidential information while balancing the need for transparency or academic dissemination, thereby preventing unauthorized disclosures and managing reputational or competitive risks.
Access and Publication. 7.1 Records will be made available for public consultation free of charge in the search room, during its advertised opening hours, subject to compliance with statutory restrictions and closure periods, security regulations and subject to the restrictions in this Agreement.
7.2 Uncatalogued Records will not normally be made accessible to the public.
7.3 Having regard to the provisions of any relevant legislation for the time being in force, copies of Records may be made by or supplied to members of the public by Cumbria Archives, on payment of an appropriate charge, for use only in private study. Copies will not be provided or allowed to be made if Cumbria Archives considers that the process will in any way damage the Records.
7.4 Where it is known that a researcher is likely to publish the results of his work, he is advised that use of the manuscripts must be appropriately acknowledged. If there are to be passages of direct transcription in the published work, beyond the use of standard short quotations or illustrations of records, the researcher is advised that written permission from the owner to publish is required.
7.5 Cumbria Archives reserves the right to publish Records in whole or in part in its own publications and website without seeking the prior permission of the Depositor.
Access and Publication. The Consortium Agreement and IMI Intellectual Property Policy regulate access rights for all consortium partners and Target Contributing Third Parties during completion of the project and subsequent research use and/or direct exploitation. As a Target Contributing Third Party, you grant non-exclusive royalty-free access rights to the Background you have on the Target Programme to the partners within the European Screening Centre necessary for them to perform the work on your Target Programme. After expiration of the three-year exclusivity period, the following information of your QHL/IHL will be made available within the consortium via the Programme Office (Lygature): Programme Name, target, gene ID and mechanism of action. This information will be shared with the other consortium partners, however, your party name will not be disclosed. If another Partner is interested in obtaining research use rights for your Target Programme, such rights should be negotiated on Fair and Reasonable conditions in accordance with the Consortium agreement. The results of the Target Programme have to be disseminated to the public in accordance with the timelines in the Consortium agreement (in general 1 year after the end of the project). However, this does not oblige you to publish each and every data point of the work that has been done. Publication of scientific results is subject to a defined Publication Policy and related approval process, designed to protect confidential information and limit potential conflicts with consortium partners. Review and possible IP protection measures may delay submission for publication by a maximum of 45 plus 90 days, respectively. In addition, if there is an interest by an EFPIA Participant to negotiate for a license of the results for direct exploitation, there could be an additional 180 day delay.
Access and Publication. 6.1 Records will be made available for public consultation free of charge in the searchroom, during its advertised opening hours subject to compliance with statutory restrictions and closure periods, security regulations and subject to the restrictions in this Agreement
6.2 Uncatalogued Records will not normally be made accessible to the public.
6.3 Having regard to the provisions of any relevant legislation for the time being in force, copies of Records may be made by or supplied to members of the public by the Council, on payment of an appropriate charge, for use only in private study. Copies will not be provided or allowed to be made if the Council considers that the process will in any way damage the Records.
6.4 Where it is known that a researcher is likely to publish the results of his work, he is advised that use of the manuscripts must be appropriately acknowledged. If there are to be passages of direct transcription in the published work, beyond the use of standard short quotations or illustrations of records, the researcher is advised that written permission from the owner to publish is required.
6.5 The Council reserves the right to publish Records in whole or in part in it own publications and website without seeking the prior permission of the Depositor.
Access and Publication. 1. International treaties within the EAEU, international agreements with a third party and decisions of the EAEU bodies shall be officially published on the official website of the EAEU in the way determined by the Intergovernmental Council. The date of publication of decision of the EAEU's body on the official website of the EAEU is considered to be the date of official publication of this decision. 2. No decision referred to in Paragraph 1 of this Article may not enter into force before their official publication.
Access and Publication. The Contributing Third Party Agreement regulates access rights for Contributing Third Parties during completion of the project and subsequent research use and/or direct exploitation. As a Contributing Third Party, you grant royalty-free access rights to the background (“Programme IP”) you have on the Programme to the public consortium partners within ESCulab necessary for them to perform the work on your screening Programme. Certain Research Use Access Rights on QHL results and background (“Programme IP”) need to be provided to the consortium members. After expiration of the three-year exclusivity period (subject to the EFPIA option – see below), the following information of your QHL will be made available within the consortium via Lygature. For target focused programmes: Programme Name, target, gene ID and mechanism of action; for target agnostic programmes: Programme Name, biological specimen, trigger, response of interest, and time and mode of its quantification. This information will be shared with the other consortium partners, however, your name and organisation will not be disclosed. If a consortium partner is interested in obtaining research use rights for your Programme, such rights should be negotiated on Fair and Reasonable conditions in accordance with the Contributing Third Party Agreement. Such conditions may also include time delays for granting Research Use Access Rights, which may add up to six (6) years from disclosure of the QHL results in total. The results of the Programme have to be disseminated to the public in accordance with the timelines in the Contributing Third Party Agreement. However, this does not oblige you to publish each and every data point of the work that has been done. Please note that publication of results is subject to an option right for licensing granted to EFPIA Participants, see section 3 below on the EFPIA option. Publication of scientific results is subject to a defined Publication Policy and related approval process, designed to protect confidential information of and limit potential conflicts with consortium partners. Review and possible IP protection measures may delay submission for publication by a maximum of 50 plus 90 days, respectively. In addition, if there is an interest by an EFPIA Participant to negotiate for a license of the results for direct exploitation, there could be an additional 9 months delay.